title: Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema.
abstract: Within the chronic obstructive pulmonary disease (COPD) spectrum, lung emphysema presents, as a primarily histopathologic feature, the destruction of pulmonary parenchyma and, accordingly, an increase in the airflow obstruction distal to the terminal bronchiole. Notwithstanding the significant advances in prevention and treatment of symptoms, no effective or curative therapy has been accomplished. In this context, cellular therapy with stem cells (SCs) arises as a new therapeutic approach, with a wide application potential. The purpose of this study is to evaluate the safety of SCs infusion procedure in patients with advanced COPD (stage IV dyspnea). After selection, patients underwent clinical examination and received granulocyte colony-stimulating factor, immediately prior to the bone marrow harvest. The bone marrow mononuclear cells (BMMC) were isolated and infused into a peripheral vein. The 12-month follow-up showed a significant improvement in the quality of life, as well as a clinical stable condition, which suggest a change in the natural process of the disease. Therefore, the proposed methodology in this study for BMMC cell therapy in sufferers of advanced COPD was demonstrated to be free of significant adverse effects. Although a larger sample and a greater follow-up period are needed, it is possible to infer that BMMC cell therapy introduces an unprecedented change in the course or in the natural history of emphysema, inhibiting or slowing the progression of disease. This clinical trial was registered with ClinicalTrials.gov (NCT01110252) and was approved by the Brazilian National Committee of Ethics in Research (registration no. 14764, CONEP report 233/2009).
authors.affiliation: Department of Biological Sciences, Universidade Estadual Paulista, Campus de Assis, Assis, SP, Brazil. jtrpaes@yahoo.com.br
authors.forename: João Tadeu
authors.initials: JT
authors.lastname: Ribeiro-Paes
authors.forename: Aldemir
authors.initials: A
authors.lastname: Bilaqui
authors.forename: Oswaldo T
authors.initials: OT
authors.lastname: Greco
authors.forename: Milton Artur
authors.initials: MA
authors.lastname: Ruiz
authors.forename: Monica Y
authors.initials: MY
authors.lastname: Marcelino
authors.forename: Talita
authors.initials: T
authors.lastname: Stessuk
authors.forename: Carolina A
authors.initials: CA
authors.lastname: de Faria
authors.forename: Mario R
authors.initials: MR
authors.lastname: Lago
mesh_terms: D000368:Aged; D001938:Brazil; D000069585:Filgrastim; D005541:Forced Expiratory Volume; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D011656:Pulmonary Emphysema / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D011994:Recombinant Proteins; D012720:Severity of Illness Index; D033581:Stem Cell Transplantation; D013997:Time Factors; D016896:Treatment Outcome; D014797:Vital Capacity
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim